- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 03.09. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference | 226 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments... ► Artikel lesen | |
| 15.08. | CNS Pharmaceuticals reports Q2 results | 1 | Seeking Alpha | ||
| 15.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 329 | ACCESS Newswire | Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON... ► Artikel lesen | |
| 14.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech | 288 | ACCESS Newswire | - Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| 22.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference | 277 | ACCESS Newswire | - Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in... ► Artikel lesen | |
| 22.07. | XFRA BE50: AUSSETZUNG/SUSPENSION | 242 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCNS PHARM.INC.NEW... ► Artikel lesen | |
| 22.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 22.07.2025 | 824 | Xetra Newsboard | The following instruments on XETRA do have their first trading 22.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 22.07.2025
Aktien
1 NGGTCO000002 Guaranty Trust Holding... ► Artikel lesen | |
| 21.07. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.07.2025 | 361 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 21.07.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.07.2025ISIN NameCA7703631092 ROBERTO... ► Artikel lesen | |
| 21.07. | XFRA ISIN CHANGE | 384 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS18978H4092 CNS Pharmaceuticals Inc. 21.07.2025 US18978H5081 CNS Pharmaceuticals Inc. 22.07.2025 Tausch 12:1CA86218J2048 Storm... ► Artikel lesen | |
| 18.07. | CNS Pharmaceuticals announces 1-for-12 reverse stock split | 4 | Investing.com | ||
| 18.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Reverse Stock Split | 262 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for... ► Artikel lesen | |
| 15.07. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment | 398 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
| 24.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme and Lead Product Candidate TPI 287 | 234 | ACCESS Newswire | Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS... ► Artikel lesen | |
| 05.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | 326 | ACCESS Newswire | In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire... ► Artikel lesen | |
| 16.05. | CNS Pharmaceuticals reports Q1 results | 4 | Seeking Alpha | ||
| 16.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | 447 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme... ► Artikel lesen | |
| 15.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | CNS Pharmaceuticals Stock Surges 36% On $5 Mln Public Offering Announcement | 1 | RTTNews | ||
| 13.05. | CNS Pharmaceuticals sets terms for $5 million stock offering | 3 | Investing.com |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,568 | -0,57 % | CureVac: Plötzlich im Sturzflug - was Anleger jetzt wissen müssen!!! | ||
| PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
| BIOXXMED | 0,300 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 0,876 | -1,00 % | Ocugen, Inc. - 8-K, Current Report | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,940 | -1,57 % | EQS-DD: Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.08.2025 / 17:58... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,422 | -1,40 % | Defence Therapeutics Inc.: Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth | Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| VAXART | 0,278 | 0,00 % | Vaxart's oral norovirus vaccine shows promising immune response data | ||
| BURCON NUTRASCIENCE | 1,440 | 0,00 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Sales of High-Purity Canola Protein | Vancouver, British Columbia--(Newsfile Corp. - September 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,000 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Ampligen... ► Artikel lesen | |
| IMMUNIC | 0,753 | +1,07 % | EQS-News: Immunic AG: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Patent
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
Das Unternehmen CNS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.